Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 48
Filter
1.
Hematology ; 27(1): 785-794, 2022 Dec.
Article in English | MEDLINE | ID: mdl-35802815

ABSTRACT

OBJECTIVES: Chronic graft versus host disease (chronic GVHD) still remains the leading cause of late morbidity and mortality for allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. In this retrospective study, 53 consecutive allo-HSCT patients with chronic GVHD refractory to corticosteroids were treated with extracorporeal photopheresis (ECP). METHODS: This study was performed as a retrospective single-center study. Medical records of a total of 59 patients treated with ECP for chronic GVHD were reviewed. RESULTS: Best organ responses to ECP were observed in skin, mouth mucosa, eyes and liver. Overall response rate (ORR) to ECP was 81.2% (CR 17% and PR 64.2%). Overall survival (OS) was 84.9% and 36.7%, at 1 and 3 years, respectively. Female sex appears to have an advantage on ORR. Patients achieving ORR were able to maintain their responses with a prolonged continuation of treatments for +6 and +12 months indicating the benefits of longer ECP treatment. DISCUSSION: We found that patients with chronic GVHD who were treated with ECP for 12 months or longer had a higher response rate. Our findings in line with the data reported previously suggest that patients responding to ECP should continue longer therapy schedules to achieve a better and sustained response. In our cohort, long-term ECP therapy was safe and well-tolerated with no significant adverse effects. Best responses were observed in the patients with skin, eye, liver and oral involvement. The ECP procedure offers the advantage relative to the problems with typical immunosuppressive agents. The female sex appeared to have an advantage based on the cumulative probability of the OR after ECP for chronic GVHD.


Subject(s)
Graft vs Host Disease , Hematopoietic Stem Cell Transplantation , Photopheresis , Chronic Disease , Female , Graft vs Host Disease/etiology , Graft vs Host Disease/therapy , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Photopheresis/adverse effects , Photopheresis/methods , Retrospective Studies , Transplantation, Homologous/adverse effects
2.
Ann Ital Chir ; 92: 78-87, 2022.
Article in English | MEDLINE | ID: mdl-35122427

ABSTRACT

BACKGROUND AND AIMS: The immune cells in tumor microenvironment release chemokines and cytokines which determine the immune phenotype of the tumor and play an important role in the prognosis. Present study evaluates the gene expression levels of IL-21 and IL-32 and their relations to clinicopathologic parameters in colorectal cancer. PATIENTS AND METHODS: 31(17F) patients with colorectal cancer were included. Samples were obtained from normal and tumor tissues. After RNA isolation, IL-21 and IL-32 gene expression levels were measured. Immunohistochemistry was also carried out for CD4+, CD8+ and NKcells to measure cell density. The relations between expression levels, immune cell density and differentiation, stage, presence of vascular, perineural invasion and lymph node metastasis(MLN) were investigated. RESULTS: IL-32 gene expression levels were increased in tumor tissues. IL-21 levels were found to be decreased in 50% of the patients. IL-32 levels were also increased with the stage however, it was decreased significantly with the increased number of the MLN. On the other hand, expression levels of IL-21 increased significantly with the presence of vascular invasion. CD4+ density was decreased with increased T-stage, vascular invasion whereas CD8+ density decreased only with the vascular invasion. CONCLUSIONS: IL-32 expressed by tumor microenvironment reveals that expression increased to control tumor growth, but levels are decreased with the increased number of MLNs which might be due to decreased CD4+ cell density. Changes on IL-21 and IL-32 together with the changes on immune cell density, indicate their role in tumor growth and invasion in colon cancer. KEY WORDS: Colorectal Cancer, Cytokines, Immune Cell Density, Interleukin-21, Interleukin-32, Tumor Microenvironment.


Subject(s)
Colorectal Neoplasms , Interleukins , Colorectal Neoplasms/genetics , Colorectal Neoplasms/pathology , Gene Expression , Humans , Interleukins/genetics , Prognosis , Tumor Microenvironment
4.
Hematology ; 19(8): 433-4, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25415427
5.
Hematology ; 18(4): 217-23, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23394612

ABSTRACT

In chronic myeloid leukemia (CML), epigenetic modifications such as promoter hypermethylation and inactive histone modification are known mechanisms of drug resistance. In our study, we investigated the roles of promoter hypermethylation of BIM and BID genes and H3K27me3 histone modification on imatinib resistance. We detected higher expression levels of BIM and BID genes and lower expression levels of EZH2, EED2, SIRT1, and SUZ12 genes in imatinib-resistant K562/IMA-3 cells compared to imatinib-non-resistant K562 cells. While we determined the EZH2 and DNMT enzymes as bounded to the promoter of the BIM gene, we did not detect hypermethylation of this promoter. We also found the H3K27me3 histone modification promoter of BIM and BID genes in both cell lines. In conclusion, our results support the notion that DNA promoter methylation may be formed independently from EZH2-H3K27me3 and pro-apoptotic BIM and BID genes are not methyllated in the imatinib resistance of CML cells.


Subject(s)
Apoptosis Regulatory Proteins/genetics , BH3 Interacting Domain Death Agonist Protein/genetics , Benzamides/pharmacology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Membrane Proteins/genetics , Piperazines/pharmacology , Proto-Oncogene Proteins/genetics , Pyrimidines/pharmacology , Apoptosis/genetics , Apoptosis Regulatory Proteins/biosynthesis , Apoptosis Regulatory Proteins/metabolism , BH3 Interacting Domain Death Agonist Protein/biosynthesis , BH3 Interacting Domain Death Agonist Protein/metabolism , Bcl-2-Like Protein 11 , Cell Line, Tumor , DNA Methylation , Drug Resistance, Neoplasm , Epigenomics , Humans , Imatinib Mesylate , K562 Cells , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/metabolism , Membrane Proteins/biosynthesis , Membrane Proteins/metabolism , Promoter Regions, Genetic , Proto-Oncogene Proteins/biosynthesis , Proto-Oncogene Proteins/metabolism
6.
Med Oncol ; 30(1): 443, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23292838

ABSTRACT

Additional chromosomal abnormalities (ACAs) in Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML) are strongly associated with disease progression, but their prognostic impact and effect on treatment response are not clear. While the onset of ACAs in Ph-negative cells during treatment has been described, their origin and clinical significance remain to be clarified. Between January 2008 and January 2011, 105 patients with Ph-positive CML were analyzed. With a median follow-up of 25.5 months, 18 CML patients (17 %) with ACAs in either CP (n = 12) or advanced phases (n = 6) were identified. The median age of the patients was 53.5 years at diagnosis. ACAs were determined in Ph-positive metaphases of 12 patients and in Ph-negative metaphases of 5 patients. One patient showed trisomy 8 both in Ph-positive and in Ph-negative metaphases. The median follow-up after the detection of ACAs was 11.9 months. None of the patients carrying ACAs in their Ph-negative metaphases developed AP or BP; however, 7 out of 12 patients (58 %) having ACAs in their Ph-positive metaphases developed AP/BC at diagnosis or follow-up (p = 0.03). All the patients carrying ACAs in only Ph-negative metaphases achieved optimal response under tyrosine kinase inhibitor (TKI) therapy, whereas only 4 out of 12 patients (25 %) had optimal TKI response in patients with ACAs in Ph-positive metaphases (p = 0.009). The presence of ACAs in Ph-positive cells during TKI therapy may reflect genetic instability and therefore negatively affect OS. Conventional cytogenic analyses remain mandatory during follow-up of patients with CML under TKI therapy.


Subject(s)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Abnormal Karyotype , Adult , Aged , Antineoplastic Agents/therapeutic use , Benzamides/therapeutic use , Chromosome Aberrations , Cytogenetic Analysis , Female , Humans , Imatinib Mesylate , Male , Middle Aged , Piperazines/therapeutic use , Prognosis , Pyrimidines/therapeutic use , Treatment Outcome
7.
Cytokine ; 61(2): 572-7, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23159284

ABSTRACT

Granulocyte-colony stimulating factor (G-CSF) has become the most effective agent supporting hematopoietic stem cell transplantation (HSCT). The cognate interaction between G-CSF and its specific receptor, G-CSFR, induces the mobilization of HSCs and increases their pool in the peripheral blood. G-CSFR has a highly conserved structure which may be functionally modulated by the presence of missense single nucleotide polymorphisms (SNPs). In this study, we asked whether the missense SNPs in G-CSFR could affect the response to G-CSF in HSCT patients and donors. Here, for the first time, G-CSFR missense SNPs were screened and minor allele frequencies were determined in a specific population with Turkish racial background. Five (rs3917991, rs3918001, rs3918018, rs3918019, and rs146617729) out of 16 missense SNPs screened were determined with minor allele frequencies lower than 0.04. Subsequent association analyses indicated potential impact of rs3918001, rs3918018, and rs3918019 minor alleles on peripheral blood CD34(+) cell enrichment. Although their frequency is rather low, certain missense SNPs, especially which are placed in the conserved regions of G-CSFR may possess the capacity to influence the response to G-CSF treatment.


Subject(s)
Hematopoietic Stem Cells/cytology , Polymorphism, Single Nucleotide/genetics , Receptors, Colony-Stimulating Factor/genetics , Adult , Antigens, CD34/metabolism , Female , Gene Frequency/genetics , Haplotypes/genetics , Hematopoietic Stem Cell Transplantation , Hematopoietic Stem Cells/metabolism , Humans , Male , Middle Aged
8.
Turk J Haematol ; 30(2): 188-90, 2013 Jun.
Article in English | MEDLINE | ID: mdl-24385784

ABSTRACT

UNLABELLED: The incidence of deep vein thrombosis (DVT) after non-myeloablative (NMA) allogeneic stem cell transplantation (allo-SCT) is unknown. In addition, very few studies on the predisposing factors for DVT post SCT have been published. The incidence of DVT among patients that underwent NMA allo-SCT at our hospital was 4.1% (3 of 73) over the course of last 8 years, and to the best of our knowledge this is the first study to report the incidence of DVT following NMA allo-SCT. The present findings show that NMA allo-SCT patients may have multiple risk factors for DVT. Herein we present 3 cases of DVT following NMA allo-SCT and a literature review. CONFLICT OF INTEREST: None declared.

9.
Hematology ; 17 Suppl 1: S159-62, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22507809

ABSTRACT

Hemostatic changes and thrombotic events are frequent in patients undergoing stem cell transplantation. Arterial and venous thromboses are major causes of morbidity and mortality. Thrombotic complications can be classified into four groups including: catheter-related thrombosis, venous thromboembolic (VTE) events, sinusoidal obstructive syndrome (SOS)/veno-occlusive disease, and transplant-associated thrombotic microangiopathy (TAM). The incidence of catheter-related thrombosis is 8-20% in patients undergoing autologous hematopoietic stem cell transplantation (HSCT), and the incidence is low in syngeneic and allogeneic transplant patients. Venous duplex Doppler ultrasound, venogram, and computed tomography scan are required to visualize the venous thrombus. The treatment should be aimed at the prevention of pulmonary embolism, the avoidance of thrombus extension, and the preservation of catheter patency. Patients undergoing HSCT may have risk factors for VTE including underlying malignancy, traumatic brain injury, prolonged hospitalization, administration of conditioning regimens, and central venous catheters. Important risk factors are presence of history of VTE and graft-versus-host disease. One-year incidence of symptomatic VTE is 3.7%. SOS, also known as veno-occlusive disease, is a serious liver disease, seen in approximately 50-60% of HSCT patients. The mortality rate from the severe form of SOS is 84.3% and majority of the patients have multi-organ failure. The frequency is quite low after autologous transplantation. Risk factors for SOS include pre-existing hepatic damage, previous high-dose chemotherapy and abdominal irradiation, female gender and donor-recipient human leukocyte antigen disparity. Cyclophosphamide and busulphan are the most common agents with the highest incidence and fatal SOS. Histopathologic features of SOS include dilatation of sinusoids, necrosis of perivenular hepatocytes, and obstruction of small intrahepatic central venules by microthrombi and fibrin deposition. Signs of SOS usually occur within first 30 days after HSCT including hyperbilirubinemia, hepatomegaly, ascites, and weight gain. Symptoms of liver failure, including encephalopathy, coagulopathy, and renal failure will appear in severe form. A hepatic venous pressure gradient above 10 mmHg is highly specific for SOS. Early use of defibrotide has been shown to be effective in the treatment of high-risk SOS. TAM is a distinct, infrequent, and significant life-threatening complication of HSCT. TAM is seen in the range of 0·5-76% and was reported to be 10-25% in patients undergoing allogeneic HSCT with a mortality rate around 50%. It can also be seen after autologous HSCT and mainly affects the glomerular capillaries. There has been no standard therapy for TAM. Few case series reported good response to rituximab and high-dose corticosteroids were used with limited success. Trials with complement inhibitors such as eculizumab are currently underway.


Subject(s)
Stem Cell Transplantation/adverse effects , Thrombosis/etiology , Catheters/adverse effects , Hepatic Veno-Occlusive Disease/diagnosis , Hepatic Veno-Occlusive Disease/etiology , Humans , Thrombosis/diagnosis , Thrombotic Microangiopathies/diagnosis , Thrombotic Microangiopathies/etiology , Venous Thromboembolism/diagnosis , Venous Thromboembolism/etiology
11.
Head Neck ; 34(3): 393-7, 2012 Mar.
Article in English | MEDLINE | ID: mdl-21472884

ABSTRACT

BACKGROUND: The aim of this study was to investigate the biology of laryngeal squamous cell carcinoma (SCC) to develop effective novel treatment modalities. METHODS: Serum concentrations of interleukin (IL)-10, IL-12, and transforming growth factor-ß (TGF-ß) were evaluated in 50 patients with laryngeal SCC and 15 controls. Results were compared according to tumor-node-metastasis (TNM) classification criteria. RESULTS: IL-12 and TGF-ß levels were not different between the early- and late-stage patients and controls. Tumor classification or nodal involvement was not associated with IL-12 and TGF-ß levels. Patients with laryngeal SCC had significantly more detectable serum IL-10 levels than those of controls, given that IL-10 could be detected in only 1 early-stage and 9 late-stage patients, but not in the control group (p = .003). IL-10 was increasingly detectable with advanced T classification (p = .009) and nodal involvement (p = .008). CONCLUSIONS: Serum IL-12 or TGF-ß levels were not affected with disease activity and classification; however, serum IL-10 levels were correlated with both parameters.


Subject(s)
Carcinoma, Squamous Cell/blood , Interleukin-10/blood , Interleukin-12/blood , Laryngeal Neoplasms/blood , Transforming Growth Factor beta/blood , Adult , Aged , Carcinoma, Squamous Cell/pathology , Case-Control Studies , Enzyme-Linked Immunosorbent Assay , Female , Humans , Laryngeal Neoplasms/pathology , Male , Middle Aged , Neoplasm Staging
12.
World J Gastroenterol ; 17(27): 3220-8, 2011 Jul 21.
Article in English | MEDLINE | ID: mdl-21912471

ABSTRACT

AIM: To investigate the expression levels of lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1), vascular endothelial growth factor receptor-3 (VEGFR-3) and CD44 genes and the relationship between their levels and clinicopathological parameters in gastric cancer. METHODS: Tissue samples were obtained from 33 patients (8 females) with gastric cancer. mRNA levels of LYVE-1, VEGFR-3 and CD44 in normal and tumor tissues were quantitatively measured using real time polymerase chain reaction. The results were correlated with lymph node metastasis, histological type and differentiation of the tumor, T-stage, and presence of vascular, perineural and lymphatic invasions. The distribution of molecules in the tissue was evaluated using immunohistochemistry. RESULTS: LYVE-1, CD44 and VEGFR-3 gene expression levels were significantly higher in gastric cancer than in normal tissue. While there was no correlation between gene expressions and clinicopathologic features such as histologic type, differentiation and stage, gene expression levels were found to be increased in conjunction with positive lymph node/total lymph node ratio and the presence of perineural invasion. A significant correlation was also found between LYVE-1 and CD44 over-expressions and perineural invasion and lymph node positivity in gastric cancers. When the distribution of LYVE-1 antibody-stained lymphatic vessels in tissue was evaluated, lymphatic vessels were located intra-tumorally in 13% and peri-tumorally in 27% of the patients. Moreover, lymph node metastases were also positive in all patients with LYVE-1-staining. CONCLUSION: LYVE-1, VEGFR-3 and CD44 all play an important role in lymphangiogenesis, invasion and metastasis. LYVE-1 is a perfectly reliable lymphatic vessel marker and useful for immunohistochemistry.


Subject(s)
Gene Expression Regulation, Neoplastic , Hyaluronan Receptors/biosynthesis , Stomach Neoplasms/metabolism , Vascular Endothelial Growth Factor Receptor-3/biosynthesis , Vesicular Transport Proteins/biosynthesis , Adult , Aged , Female , Humans , Immunohistochemistry/methods , Lymphatic Metastasis , Male , Middle Aged , Prognosis , RNA, Messenger/metabolism
13.
Cytotechnology ; 61(1-2): 45-53, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19967401

ABSTRACT

Gene transfer into haematopoietic cells is a challenging approach. The extracellular matrix component fibronectin has been known to modulate the cell cycle dynamics, viability and differentiation of leukaemia cells. Thus, our aim was to investigate the influence of fibronectin substratum on the liposomal transfection of myeloid leukaemia cell lines. Liposomal transfection was performed with K562 and HL-60 as representative lines of transfection-competent and -incompetent myeloid leukaemia cells, respectively. Flow cytometry analyses were performed to determine transfection efficiency monitored by green fluorescent protein (GFP) expression and to assess cell viability and cell cycle status. Quantitation of GFP gene expression and DNA uptake was assayed by real time PCR. The current data showed that the adhesion to fibronectin deteriorated the transfection of K562 cells. In contrary, it enhanced the delivery of plasmid DNA into HL-60 cells. Correspondingly, the adhesion to fibronectin influenced the transfection efficiency mainly by modulating the intracellular presence of plasmid DNA. The cell cycle and viability which is regulated by fibronectin had a minor impact on the success of gene delivery. This phenomenon may be considered as an important factor which may modulate the potential gene transfer approaches for myeloid leukaemia.

14.
Clin Transplant ; 23(6): 981-4, 2009.
Article in English | MEDLINE | ID: mdl-19689453

ABSTRACT

We present a rare experience with a myeloma patient who had a late relapse as isolated extramedullary plasmacytoma of the thyroid gland after a second allogeneic transplantation. We give PET/CT scan findings at diagnosis and during follow up of the disease after subsequent management. The possible pathogenesis of the late extramedullary relapse of myeloma after allogeneic stem-cell transplantation and management options are discussed.


Subject(s)
Immunoglobulin kappa-Chains/metabolism , Multiple Myeloma/diagnosis , Neoplasm Recurrence, Local/diagnosis , Plasmacytoma/diagnosis , Stem Cell Transplantation/adverse effects , Thyroid Neoplasms/diagnosis , Biopsy , Follow-Up Studies , Humans , Male , Middle Aged , Multiple Myeloma/metabolism , Multiple Myeloma/surgery , Neoplasm Recurrence, Local/metabolism , Plasmacytoma/metabolism , Plasmacytoma/surgery , Positron-Emission Tomography , Prognosis , Thyroid Neoplasms/metabolism , Thyroid Neoplasms/surgery , Time Factors , Transplantation, Homologous
15.
Cancer Biol Ther ; 8(2): 136-42, 2009 Jan.
Article in English | MEDLINE | ID: mdl-19164932

ABSTRACT

The presence of CD40 on carcinoma cells is an important factor for the generation of tumor-specific responses induced by CD40 ligation. In an N-methyl-N-nitrosourea (MNU)-induced autochthonous mammary tumor model, we analyzed the immune features of primary tumor cells. Here, CD40 was frequently detected on the primary tumor cultures and selectively expressed on the malignant mammary tissue in vivo. On the other hand, every mammary tumor cell culture had a heterogeneous and reduced expression of proinflammatory TNFalpha, IL-1beta, IL-6 and CXCL1 cytokines compared to normal mammary epithelial cells. Low-efficiency transfection of CD40 ligand (CD40L) gene enhanced the expression of proinflammatory cytokines in the tumor cells and strengthened allogeneic immune reactions and costimulatory activity which may help overwhelming suppressive features of the tumor.


Subject(s)
CD40 Ligand/genetics , CD40 Ligand/immunology , Carcinoma/immunology , Mammary Neoplasms, Experimental/genetics , Mammary Neoplasms, Experimental/immunology , Alkylating Agents/toxicity , Animals , Animals, Outbred Strains , Carcinoma/chemically induced , Carcinoma/genetics , Carcinoma/pathology , Cell Line, Tumor , Culture Media/chemistry , Ethidium/metabolism , Female , Fluorescent Dyes/metabolism , Green Fluorescent Proteins/genetics , Immunohistochemistry , Liposomes , Mammary Neoplasms, Experimental/chemically induced , Mammary Neoplasms, Experimental/pathology , Methylnitrosourea/toxicity , Mucin-1/immunology , Rats , Rats, Sprague-Dawley , Recombinant Proteins/immunology , Transfection/methods
16.
Int J Hematol ; 89(2): 167-172, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19160003

ABSTRACT

The extracellular matrix plays a critical role in macrophage maturation. In this study, the HL60 cell line was used as a model of leukemic myeloid cell differentiation. We assessed the ability of HL60 cells cultured on fibronectin substratum prior to phorbol 12-myristate 13-acetate (PMA) induction to differentiate into terminally differentiated macrophages. Beside their distinctive macrophage morphology, they expressed antigen receptors CD14, TLR2, TLR4 and CD68, and displayed enhanced phagocytic activity and production of reactive oxygen species. Expression of CD13, CD33, CD15 and alpha-naphthyl-acetate esterase was also maintained, however, differentiated HL60 cells were HLA-DR and CD1a negative. Here, we describe the enhanced capacity of fibronectin-adherent HL60 cells to differentiate into macrophages in response to PMA.


Subject(s)
Fibronectins/physiology , Leukemia, Myeloid/pathology , HL-60 Cells , Humans , Macrophages/cytology , Myeloid Cells/pathology , Tetradecanoylphorbol Acetate/pharmacology
17.
Clin Transplant ; 23(6): 839-47, 2009.
Article in English | MEDLINE | ID: mdl-20447186

ABSTRACT

Autologous stem-cell transplantation (ASCT) has emerged as the standard approach in patients with multiple myeloma, although it is unlikely to achieve cure. Thalidomide maintenance and non-myeloablative allogeneic transplantation (NST) may increase complete remission (CR) rate and increase overall survival. In this study, 35 ASCT and 10 NST were performed in 33 patients. Patients, who were resistant or relapsed following ASCT, underwent NST if they had an HLA-matched sibling, otherwise treated with a second ASCT. Thalidomide was started as maintenance after ASCT. After first transplantation, three patients underwent second ASCT and 10 patients underwent NST. Following first transplantation, CR rate was 39% and increased to 60% (overall response 93%) with addition of thalidomide, bortezomib, and second transplantation. CR was durable in 14 (42%) patients. During a median follow-up of 24 months, 18 patients progressed and nine patients died. The 100-d transplant-related mortality was <5%. The four-yr progression-free survival (PFS) was 52.4%. In conclusion, ASCT followed by thalidomide and NST in resistant patients can lead to high CR and PFS rates. As a second transplantation has not been performed routinely, patients having durable CR had a chance to avoid or delay a second transplantation without compromising disease control.


Subject(s)
Multiple Myeloma/surgery , Remission Induction , Stem Cell Transplantation/methods , Adult , Aged , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/therapeutic use , Boronic Acids/administration & dosage , Boronic Acids/therapeutic use , Bortezomib , Disease-Free Survival , Dose-Response Relationship, Drug , Female , Follow-Up Studies , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/therapeutic use , Male , Middle Aged , Multiple Myeloma/drug therapy , Multiple Myeloma/mortality , Pyrazines/administration & dosage , Pyrazines/therapeutic use , Survival Rate/trends , Thalidomide/administration & dosage , Thalidomide/therapeutic use , Time Factors , Transplantation, Autologous , Treatment Outcome
18.
Biol Blood Marrow Transplant ; 14(12): 1425-8, 2008 Dec.
Article in English | MEDLINE | ID: mdl-19041066

ABSTRACT

Nausea and vomiting during the infusion of cryopreserved peripheral blood stem cells (PBSC) are common. The aim of this study was to explore the effect of lollipop with strawberry aroma on the infusion-related nausea and vomiting of cryopreserved autologous PBSCs. We compared 2 groups of adult patients receiving lollipop with strawberry aroma during cryopreserved PBSC infusions or not to assess the incidences of nausea and vomiting occurring during infusions. All patients received granisetron 3 mg i.v. twice a day, and lorazepam 1 mg every 4 hours orally for prophylaxis of the nausea and vomiting during conditioning phase and infusion day. Before infusion, all patients were premedicated with pheniramine maleate 45.5 mg i.v. and paracetamol 500 mg orally. The patients had no evidence of nausea or vomiting prior to cryopreserved PBSC infusions. The patients with ongoing nausea or vomiting owing to conditioning regimens and/or receiving additional antiemetics were excluded from the study. One hundred fifty-eight patients who consecutively underwent autologous stem cell transplantation for malignancy were included in the study. The first 110 patients (median age: 42.5, range: 17-75) were observed for the infusion related adverse effects only. The consecutive 48 patients (median age: 48, range: 18-80) were given a lollipop with strawberry aroma during cryopreserved PBSC infusions and observed for the infusion-related adverse effects. The 2 groups were comparable with respect to age, sex, diagnosis, stem cell collection methods, conditioning regimens administered, total mononuclear cell dose infused, number of total nucleated cells (TNCs) infused, number of CD34+ cells infused, number of bags infused, total volume infused, amount of dimethylsulfoxide (DMSO), and infusion rate. Patients who received a lollipop with a strawberry aroma during infusions had significantly less nausea (6.3%, n = 3 versus 21.8%, n = 24, P = .02) and vomiting (2%, n = 1 versus 13.6%, n = 15, P = .04) than the ones who did not (observation only group). Other infusion-related adverse events were as follows; hypoxia, cough, dyspnea, abdominal cramping, tachycardia, hiccup, fever, chills, chest pain, hypotension, hypertension, agitation, sore throat, and arrhythmia. Incidences of each of these adverse events were <5% in both groups and were comparable. The use of a lollipop with a strawberry aroma during infusion of cryopreserved autologous PBSCs may be promising in reduction of infusion-related nausea and vomiting, with an easy administration at a very cheap cost.


Subject(s)
Candy , Cryopreservation , Hematopoietic Stem Cells , Nausea/prevention & control , Peripheral Blood Stem Cell Transplantation , Vomiting/prevention & control , Adolescent , Adult , Aged , Aged, 80 and over , Anti-Allergic Agents/administration & dosage , Cryoprotective Agents/adverse effects , Dimethyl Sulfoxide/adverse effects , Female , Fragaria , Hematologic Neoplasms/therapy , Humans , Male , Middle Aged , Nausea/chemically induced , Pheniramine/administration & dosage , Transplantation, Autologous , Vomiting/chemically induced
19.
Leuk Lymphoma ; 47(8): 1545-52, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16966265

ABSTRACT

Although high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has become the standard approach for patients with relapsed/refractory Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL), more than 50% of patients will experience relapse following ASCT. High-dose sequential chemotherapy (HDSC) can intensify the conventional salvage treatment and improve the outcome of ASCT by maximal debulking of the tumor load with the use of non-cross resistant drugs, each at their maximal tolerated doses. We conducted a phase II study in 40 patients with relapsed/refractory HD (n = 18) and NHL (n = 22) using HDSC followed by ASCT. Only patients sensitive to salvage chemotherapy were eligible for the protocol, consisting of three phases. Phase I consisted of cyclophosphamide (4.5 g/m2) followed by G-CSF and peripheral blood stem cell (PBSC) collection. Phase II consisted of etoposide (2 g/m2). The transplant phase consisted of mitoxantrone (60 mg/m2) and melphalan (180 mg/m2) followed by PBSC infusion. Eleven out of nineteen patients with B-cell lymphoma received rituximab. Prior to HDSC, 45% of the patients were in complete remission (CR) and 55% were in partial remission (PR). After completion of all phases of the protocol, 35 out of 39 evaluable patients achieved CR (90%) and this was durable in 30 (75%) patients with a projected progression-free survival (PFS) rate at 4 years of 71.7%. Treatment-related mortality rate at day +100 was 2.5% (n = 1). At a median follow-up of 32 months (range, 3 - 61), nine patients relapsed/progressed and eleven patients died. The estimated 4-year PFS and overall survival (OS) were 72.2% and 47.6% in HD patients and 70.3% and 69.4% in NHL patients, respectively. Factors predicting OS were response to conventional salvage therapy and stage prior to salvage therapy. When compared to patients achieving PR, patients who attained CR prior to HDSC had a significantly higher probability of 4-year OS (78.4% vs 31.3%, p = 0.02). Three prognostic subgroups were defined according to the score determined by stage prior to initiation of salvage chemotherapy, remission duration prior to salvage (refractory/early relapse vs. late relapse) and response to salvage. Prognostic score was found to predict OS, PFS and event free survival (EFS). In conclusion, HDSC followed by ASCT is an effective salvage therapy with acceptable toxicity, allowing further consolidation of response attained by conventional salvage therapy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Lymphoma/therapy , Peripheral Blood Stem Cell Transplantation/methods , Salvage Therapy/methods , Adolescent , Adult , Etoposide/administration & dosage , Female , Humans , Lymphoma/mortality , Male , Maximum Tolerated Dose , Melphalan/administration & dosage , Middle Aged , Mitoxantrone/administration & dosage , Peripheral Blood Stem Cell Transplantation/mortality , Prognosis , Remission Induction , Salvage Therapy/mortality , Survival Analysis , Transplantation, Autologous
SELECTION OF CITATIONS
SEARCH DETAIL
...